Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics.
We are leveraging the power of our proprietary NAM technology to create allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. Our proprietary technology enhances and expands cells while maintaining their intrinsic properties, enabling us to create potentially transformative cell therapies that go beyond what is possible with existing approaches.
The proof of concept of this approach has been validated in our FDA-approved therapy and is being investigated in clinical trials for GDA-201.
How Gamida Cell Uses and Maintains Information Collected from its Clinical Trials
Gamida Cell collects, processes and transfers personal data to and from its investigational clinical sites in accordance with applicable state, federal and international law governing investigational drugs and the use and disclosure of protected health information.
Clinical data collected from Gamida Cell’s clinical studies pertaining to a specific study participant is generally anonymized using a code or other method specifically assigned to each study participant to ensure that they cannot be identified. This applies to activities involving the processing of personal data by or on behalf of Gamida Cell, and in any format whether electronic or paper, regardless of storage location and means.
Study records that identify a study participant will be kept confidential as required by, and in accordance with, applicable law. While the information and data generated from a Gamida Cell clinical study may be presented at scientific meetings or published in a scientific journal, a study participant’s identity will not be revealed.
A description of each Gamida Cell clinical trial is available on http://www.ClinicalTrials.gov, as required by U.S. Law. This website will not include information that can identify study subjects.
View Our Pipeline